Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of inulin, a prebiotic dietary fiber, and metronidazole, an antibiotic and antiprotozoal agent. In clinical research settings, this combination has been studied for its potential to modulate the gut microbiome and improve metabolic parameters in conditions such as non-alcoholic fatty liver disease (NAFLD). The rationale is that short-term administration of metronidazole reduces dysbiotic gut bacteria, followed by inulin supplementation to promote beneficial bacterial growth. Metronidazole acts by disrupting DNA synthesis in anaerobic bacteria and protozoa, while inulin serves as a fermentable substrate for beneficial colonic bacteria[1][2][3][4][5]. This combination does not have an established brand or unique product name on the market but has been used experimentally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on inulin + metronidazole.